Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses

OBJECTIVE: To compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate responders to csDMARDs (csDMARD-IR) or tumour ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Choy, Ernest, Freemantle, Nick, Proudfoot, Clare, Chen, Chieh-I, Pollissard, Laurence, Kuznik, Andreas, Van Hoogstraten, Hubert, Mangan, Erin, Carita, Paulo, Huynh, Thi-Minh-Thao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397432/
https://www.ncbi.nlm.nih.gov/pubmed/30886733
http://dx.doi.org/10.1136/rmdopen-2018-000798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397432/
https://www.ncbi.nlm.nih.gov/pubmed/30886733
http://dx.doi.org/10.1136/rmdopen-2018-000798

Ejemplares similares